IRLAB’s Mesdopetam Displays Antipsychotic Properties in an Advanced Model of Parkinson’s Disease Psychosis - Seite 2

About the journal Neurotherapeutics

Neurotherapeutics is the journal of the American Society for Experimental Neurotherapeutics (ASENT). The journal publishes original research articles in translational neuroscience including descriptions of cutting edge therapies that cross disciplinary lines and represent important contributions to neurotherapeutics for medical practitioners and other researchers in the field.

About IRLAB

IRLAB is discovering and developing a portfolio of transformative therapies targeting all stages of Parkinson's disease. The company has its origin in Nobel Laureate Prof. Arvid Carlsson's research group and the discovery of a connection between the brain's neurotransmitters and CNS disorders. Mesdopetam (IRL790), in development for the treatment of levodopa-induced dyskinesias, has completed Phase IIb and is in preparation toward Phase III. Pirepemat (IRL752), is currently in Phase IIb, being evaluated for its effect on balance and fall frequency in Parkinson's disease. In addition, the company is also progressing the three preclinical programs IRL757 (financially supported by the Michael J. Fox Foundation), IRL942, and IRL1117 towards Phase I studies. IRLAB's pipeline has been generated by the company's proprietary systems biology-based Integrative Screening Process (ISP) research platform. Headquartered in Sweden, IRLAB is listed on Nasdaq Stockholm (IRLAB A). For more information, please visit www.irlab.se .

Attachments

IRLAB's mesdopetam displays antipsychotic properties in an advanced model of Parkinson's disease psychosis

SOURCE: IRLAB Therapeutics

View the original press release on accesswire.com


The IRLAB Therapeutics Stock at the time of publication of the news with a fall of -4,40 % to 1,630EUR on Frankfurt stock exchange (18. März 2024, 08:37 Uhr).